BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that further to the review by the Ontario Securities Commission (“OSC”) of the Company’s continuous disclosure record, and a subsequent request from staff of the OSC in connection therewith, the Company has filed corrective disclosure with respect to the following documents: management’s discussion and analysis for the year ended February 28, 2022 and management’s discussion and an